BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Flu is rising rapidly, driven by a new variant. Here's what to know - 2New method spots signs of Earth's primordial life in ancient rocks
- 3Track down the Ideal Weight reduction Methodology for Your Way of life
- 4'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here
- 5Vote In favor of Your #1 Method for diminishing Pressure
- Solid Propensities: Little Changes for a Superior Life
- Must-See Attractions in Washington, D.C.
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- Manual for 6 famous sorts of cheddar
- Woman gives birth on roadside after hospital allegedly sent her home: Family
- 4 well known subjects in school
- Far-right AfD invited back to Munich Security Conference in 2026
- Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- Poll: Most are satisfied with their health insurance, but a quarter report denials or delays
